DOCSLIB.ORG

Nootropics - Smart Drugs Cheat Sheet by [Deleted] Via Cheatography.Com/8051/Cs/1179

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nootropics - Smart Drugs Cheat Sheet by [Deleted] Via Cheatography.Com/8051/Cs/1179 Nootropics - Smart Drugs Cheat Sheet by [deleted] via cheatography.com/8051/cs/1179/ Nootropics Dictionary (cont) Dictionary (cont) Giurg​ ea's Nootropic Criteri​ a: Neur‐​ Chemical released by neurons to Ago A chemical substance (as a drug) Enhances learning and memory. otr‐​ stimulate neighbo​ uring neurons, ni​ st capable of combining with a Enhances learned behaviors under ans‐​ allowing impulses to be passed receptor on a cell and initiating the conditions which are known to disrupt mit‐​ from one cell to the next same reaction or activity typically them (e.g. hypoxia (oxygen deficie​ ncy)). ter throughout the nervous system. A produced by the binding of an Protects the brain from physical or nerve impulse arriving at the axon endogenous substance. chemical injury. Enhances the tonic terminal of one neuron stimulates cortica​ l/s​ ubc​ ort​ ical control mechanisms release of a neurotr​ ans​ mit​ ter, Natural Nootropics which crosses the microsc​ opic gap Exhibits few side effects and extremely Bacopa Bacopa also is an effective (see synapse) in millise​ conds to low toxicity, while lacking the pharma‐​ Monnieri antioxi​ dant and has been used the adjoining neuron's dendrite. cology of typical psychot​ ropic drugs in a number of anti-aging For example acetylc​ hol​ ine, (motor stimula​ tion, sedation, etc.). formulas. The primary medical dopamine, and serotonin. What's nootropic ?: ingredient derived from the Inha‐​ An agent that slows or interferes Bacopa Monnieri plant is the Nootrop​ ics, also known as smart drugs, bitor with a chemical reaction, a bacopas​ apo​ nins alkaloid. are cognitive enhancers. They improve substance that reduces the activity Studies of this drug show that it mental functions cognition, memory, of another substance (as an can improve several different intelli​ gence, motivat​ ion, attention, focus, enzyme), a gene that checks the factors related to memory at the concent​ rat​ ion, alertness and more. normal effect of another nonallelic same time including memory Read more at nextgen​ -hu​ man​ .com gene when both are present. formation, retention of concepts, MAO- Inhibitor of the enzyme monoamine and restora​ tion. The effects of Dictionary B oxidase B. MAO-B helps break Bacopa as a Nootropic will be Ada Natural metabolic regulators that inhib down dopamine; inhibiting it best experie​ nced with long-term p‐​ increase the ability of organism to it​ or prolongs the action of dopamine in consistent usage. tog‐​ adapt to environ​ mental factors and the brain. ens to avoid damage from such factors. Prec‐​ A substance, cell, or cellular Nontoxic substance and especially ursor component from which another a plant extract that is held to substance, cell, or cellular increase the body's ability to resist component is formed especially by the damaging effects of stress and natural processes. promote or restore normal physio‐​ Cofa‐​ A substance that acts with another logical functio​ ning. ctor substance to bring about certain effects. By [deleted] Published 9th August, 2013. Sponsored by CrosswordCheats.com cheatography.com/deleted- Last updated 11th May, 2016. Learn to solve cryptic crosswords! 8051/ Page 1 of 6. http://crosswordcheats.com Nootropics - Smart Drugs Cheat Sheet by [deleted] via cheatography.com/8051/cs/1179/ Natural Nootropics (cont) Natural Nootropics (cont) Natural Nootropics (cont) Huperz​ Has been used for its nootropic Gingko The ginkgo tree leaves contain The Mushroom (known by the scientific ine-A benefits for hundreds of years, it bilboa terpenoids and flavonoid Lion’s name of Hericium erinaceus) is an is only recently that we discovered glycosides which act as Mane edible mushroom that grows in the mechanism of action of this monoamine oxidase inhibit​ ors. North America. Lion’s Mane is supplem​ ent. Huperzi​ ne-A blocks Ginkgo also improves circula​ tion popular in traditi​ onal Chinese the production of acetylc​ hol​ ine​ st‐​ throughout the body, protects medicine serving as an antioxi​ dant erase – a chemical which breaks organs from free radicals and and helping to regulate blood lipid down the neurotr​ ans​ mitter Acetyl‐​ oxidative damage to the cells and and blood glucose levels. Pills choline when there is too much of may be able to prevent the made from Lion’s Mane are even it. By inhibiting certain receptors formation of blood clots. Ginkgo used to treat gastric ulcers. For that control the amount of acetyl‐​ Biloba has proven effective at those interested in the nootropic chol​ ine​ ste​ rase produced, Huperz‐​ enhancing cognition in patients benefits of this mushroom, a 2009 ine-A is therefore able to indirectly diagnosed with dimension and is study from Phytoth​ erapy Research affect acetylc​ holine levels. Higher used to boost the memory and found that taking this mushroom amounts of acetylc​ holine lead to concent​ rat​ ion. While it may not resulted in improved cognitive improved cognition and learning be as strong as other nootrop​ ics, ability. Other studies have shown scores as well as better memory. it is a good addition to any natural that Lion’s Mane increases nerve Acetylc​ holine also plays a role in nootropic stack. growth factor secreti​ ons. NGF is a protecting brain cells from dying protein that is vital to the growth as well as being necessary in the and mainten​ ance of neurons in the formation of new brain cells. brain, contrib​ uting to long-term brain health. By [deleted] Published 9th August, 2013. Sponsored by CrosswordCheats.com cheatography.com/deleted- Last updated 11th May, 2016. Learn to solve cryptic crosswords! 8051/ Page 2 of 6. http://crosswordcheats.com Nootropics - Smart Drugs Cheat Sheet by [deleted] via cheatography.com/8051/cs/1179/ Natural Nootropics (cont) Nootropics Types (cont) Nootropics Types (cont) Yerba Enhance alertness and mental Dop A)M​ et​ abolic precurs​ ors: L-Phen‐​ Choli​ ne‐​ A)P​ re​ cur​ sors: Choline, DMAE, Mate acuity without stimula​ nt-​ type side a‐​ ylal​ anine, L-Tyros​ ine, L-DOPA, rgics Meclofe​ nox​ ate, Alpha-GPC B)‐​ effects, like nervous​ ness. Yerba min‐​ Biopterin, Pyridox​ al-​ pho​ sphate B)‐​ Cof​ act​ ors: Acetylc​ arn​ itine, mate, appears to give your brain a erg‐​ Reu​ ptake inhibit​ ors: Aminept​ ine, Vitamin B5 C)A​ ce​ tyl​ cho​ lin​ es‐​ boost without making you nervous. ics Methylp​ hen​ idate, Bupropion C)‐​ terase inhibit​ ors: Galanta​ mine, You feel alert and sharp. Interes​ ti‐​ MAO-B inhibit​ ors: Selegil​ ine, Ipidacrine (Neirom​ idin), Lycoris ngly, it actually works as a tonic for Rasagil​ ine, Rhodiola rosea D)D​ o‐​ radiata (Red Spider Lily), the central nervous system, pamine agonists: Ropinir​ ole, Huperzine A, Donepezil, calming the body and the mind. It Pramipe​ xole, Amisulp​ ride E)O​ t‐​ Rosemary, Sage, Celastrus has also been shown to improve hers: Mucuna pruriens (Velvet Panicul​ atus, Cannabis D)R​ e‐​ mood and concent​ rat​ ion, reduce Bean), Modafinil: Citicoline uptake inhibit​ ors and anxiety, and prevent mental Stim​ A)A​ mp​ het​ ami​ nes: Ampheta​ mine enhancers: Colurac​ etam, fatigue. A typical cup contains up to ula‐​ (Adderall, Dexedri​ ne), Lisdexa​ mf‐​ Ginseno​ sides Source, 10 times more of this stimulant than nts etamine (Vyvanse), Methamp​ he‐​ Agonists, Isproni​ cline, Nicotine, there is caffeine in a cup of coffee. tamine (Desoxyn) B)A​ dr​ ene​ rgi​ cs: Arecoline Source: bestnoo​ tro​ pic​ .org Atomoxe​ tine, Reboxet​ ine, GABA Suritoz​ ole, A5IA Synephrine (found in Bitter orange) blockers Movie Drugs (fiction) C)C​ ho​ lin​ erg​ ics: Arecoline, Nicotine Glut‐​ CX-717, IDRA-21, LY-503,430 D)E​ ug​ ero​ ics ("Wak​ efu​ lness NZT-48, With the help of a mysterious pill amate Enhance​ rs"​ ): Adrafinil, Armodaf​ inil, Limitless that enables the user to access activa‐​ Modafinil E)X​ an​ thi​ nes: (reduces 100 percent of his brain abilities, tors fatigue percept​ ion): Caffeine, a struggling writer becomes a cAMP Propent​ ofy​ lline, Rolipram, Paraxan​ thine, Theobro​ mine, financial wizard, but it also puts Mesembrine Theophy​ lline him in a new world with lots of Serot​ on‐​ A)P​ re​ cur​ sors: 5-HTP, dangers. ergi​ cs Tryptophan B)C​ of​ act​ ors: Source: imdb.com Pyridoxal C)R​ eu​ ptake inhibi‐​ tors: SSRIs, Sceletium Nootropics Types tortuosum, Hypericum perforatum D)M​ AO-A inhibit​ ors: Racet​ ams piracetam, oxirace​ tam, Resvera​ trol, Curcumin, phenylp​ ira​ cetam, anirace​ tam, Piperine, Harmal, Rhodiola nefirac​ etam rosea E)R​ eu​ ptake enhance​ rs: Vitamins B Vitamins, Omega - 3, Tianeptine and Isoflav​ ones, Vitamin D supple‐​ ments By [deleted] Published 9th August, 2013. Sponsored by CrosswordCheats.com cheatography.com/deleted- Last updated 11th May, 2016. Learn to solve cryptic crosswords! 8051/ Page 3 of 6. http://crosswordcheats.com Nootropics - Smart Drugs Cheat Sheet by [deleted] via cheatography.com/8051/cs/1179/ Nootropics Types (cont) Nootropics Types (cont) WWW sources (cont) Anti-​ st‐​ Beta blockers, Lemon Balm, Direct Vasopre​ ssin, Pregnen​ olone, https:/​ /en​ .wi​ kip​ edi​ a.o‐​ Wikipedia site ress Passion Flower, Rhodiola Rosea, hormones Orexin rg/​ wik​ i/N​ oot​ ropic about nootrop​ ics. St John's Wort, Ginseng Seco‐​ DHEA http://​ www​ .no​ otr​ op‐​ Very big list of (including Siberian ginseng), ndary ics.com​ /re​ fs/​ ind​ ex.html smart drugs. Sutherl​ andia frutesc​ ens, Kava— enhanc‐​ http://​ bra​ inm​ eta​ .co​ m/‐​ Forum about an​ xio​ lytic herb, Tea, Theanine, ers forum/ cognitive Grape seed extract, Adafen‐​ Unknown Bacopa monniera (Brahmi), enhancers. oxate, Phenibut, Picamilon, enhanc‐​ Clitoria ternatea (Shankh​ pu‐​ http://​ www​ .lo​ nge​ cit​ y.o‐​ Another forum Valerian, Butea frondosa, Gotu ement shpi), Fipexide, Gerovital H3, rg/​ for​ um/​ for​ um/​ 169​ -b‐​ about cognitive Kola, Foti, Panax ginseng, Sulbuti​ amine, Royal Jelly, rain​ -he​ alth/ enhancers. Chinese herbs such as Polygala Curcumin tenuifo​ lia, Acorus gramineus and Adapt​ og‐​ Holy Basil, Tulsi, Ginseng, About this cheatsheet Huperzia serrata, Bacopa ens Rhodiola rosea, Ashwaganda monnieri, Tulsi (Ocimum This document is a summary of a number of (Withania somnife​ ra), Reishi sanctum, sweet holy basil) articles from various sources about the "‐​ (Ganoderma lucidum) Blood Blessed Thistle, Coenzyme q-10, Smart Drugs".
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,148,546 B2 Schuster Et Al
    US008148546B2 (12) United States Patent (10) Patent No.: US 8,148,546 B2 Schuster et al. (45) Date of Patent: Apr. 3, 2012 (54) TETRAHYDROCARBAZOLE DERIVATIVES (58) Field of Classification Search .................. 548/448: ASLGANDS OF G-PROTEIN COUPLED 51474 11 RECEPTORS See application file for complete search history. (75) Inventors: Tilmann Schuster, Grossostheim (DE); Klaus Paulini, Maintal (DE); Peter (56) References Cited Schmidt, Schoeneck (DE); Silke Baasner, Schoeneck (DE); Emmanuel FOREIGN PATENT DOCUMENTS Polymeropoulos, Frankfurt (DE); WO WO O3051837 * 6, 2003 Eckhard Guenther, Maintal (DE); WO WO 2006005484 * 1, 2006 Michael Teifel, Weiterstadt (DE) OTHER PUBLICATIONS (73) Assignee: AEterna Zentaris GmbH, Frankfurt Kubinyi (3D QSAR in Drug Design: Ligand-Protein Interactions and (DE) Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages), TOC, pp. 243-244 provided.* *) NotOt1Ce: Subjubject to anyy d1Sclaimer,disclai theh term off thisthi Tatsuta et al. (Bioorg. Med. Chem. Lett. 15 (2005) 2265-2269).* patent is extended or adjusted under 35 Wermuth, The Practice of Medicinal Chemsitry, 2d ed. (2003), 768 U.S.C. 154(b) by 852 days. pages, chs. 9-10 provided.* CAPLUS Abstract of WO O3051837.* (21) Appl. No.: 12/109,479 * cited by examiner (22) Filed: Apr. 25, 2008 (65) Prior Publication Data Primary Examiner — Robert Havlin (74) Attorney, Agent, or Firm — Oblon, Spivak, US 2009/O 170783 A1 Jul. 2, 2009 McClelland, Maier & Neustadt, L.L.P. Related U.S. Application Data (60) Provisional application No. 60/914,424, filed on Apr. (57) ABSTRACT 27, 2007. The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein (30) Foreign Application Priority Data coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological con Apr.
    [Show full text]
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • Supplementary Digital Content REVIEW of ANXIETY MODELS USED in 2010-2011. Type of the Study. Here We Cathegorize the Study Accor
    Supplementary digital content REVIEW OF ANXIETY MODELS USED IN 2010-2011. LEGEND Type of the study. Here we cathegorize the study according to its major aim or major finding as follows: anxiogenic effects, the compound had effects opposite to expectations; detection of anxiolytic effect, anxiolytic effects were noticed but no suggestion was formulated for use as anxiolytics; established anxiolytic, well-known anxiolytics studied for various reasons; no effect on anxiety, the compound did not fulfil expectations; mechanism, studies employing anxiolytic treatments but addressing developmental issues, neural mechanisms, drug interactions etc.; putative novel anxiolytic, the authors suggested the compound for anxiolytic drug development; (H), the tested compound was an herbal extract; (Ho), purified or synthesized compound of herbal origin. Anxiety tests. The tests listed in Table 1 were considered 'classical' for the reasons specified in the Abstract. Modifier. Tests are sometimes performed under unconventional conditions to induce heightened levels of anxiety and by this to icrease the translational value of the test. Procedures that altered (usually increased) anxiety levels normally shown in the given test were categorized as follows. chemical, hormonal or pharmacological treatments (e.g. ovarectomy, drug administration in adolescence, etc.); condition, modified testing conditions (e.g. high lighting, no habituation to the testing room, etc.); neural, treatments that affect neural functions (e.g. brain lesions, inhibited neurogenesis); selection, subjects from selection lines, specific strains, etc; stress, subjects exposed to stressors with long-lasting consequences (e.g. chronic immobility, drug withdrawal, etc); subject, the use of specific subjects classes (aged subjects, females, etc.); transgenic, the effects of drugs were studied in genetically engineered subjects.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Semax Item No. 27719 CAS Registry No.: 80714-61-0 N Formal Name: L-methionyl-L-α-glutamyl- N H S L-histidyl-L-phenylalanyl-L- H2N prolylglycyl-L-proline O Synonym: ACTH4-7-PGP N H N N O MF: C37H51N9O10S O FW: 813.9 H N OH N O H Purity: ≥95% N O O O Supplied as: A solid H Storage: -20°C O HO Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Semax is supplied as a solid. A stock solution may be made by dissolving the semax in the solvent of choice, which should be purged with an inert gas. Semax is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of semax in these solvents is approximately 5 and 1 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of semax can be prepared by directly dissolving the solid in aqueous buffers. The solubility of semax in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Semax is a synthetic peptide analog of adrenocorticotropic hormone (ACTH) (4-10) (Item No. 27106) that has neuroprotective, analgesic, and anxiolytic properties.1-3 In vivo, semax (0.3 mg/kg) reduces cortical nitric oxide (NO) production and the number of neurological disturbances, such as seizures, falling, and twisting, in a rat model of global ischemia.1 It decreases acetic acid-induced writhing and nociception in a hind paw compression test in mice when administered at doses ranging from 0.015 to 0.5 mg/kg.2 Semax also increases time spent in the open arms in the elevated plus maze, indicating anxiolytic activity, in a rat model of maternal deprivation-induced anxiety.3 References 1.
    [Show full text]
  • Effects of Semax on Dopaminergic and Serotoninergic Systems of the Brain K
    Doklady Biological Sciences, Vol. 394, 2004, pp. 1–3. Translated from Doklady Akademii Nauk, Vol. 394, No. 1, 2004, pp. 130–132. Original Russian Text Copyright © 2004 by Eremin, Kudrin, Grivennikov, Miasoedov, Rayevsky. PHYSIOLOGY Effects of Semax on Dopaminergic and Serotoninergic Systems of the Brain K. O. Eremin*, V. S. Kudrin*, I. A. Grivennikov**, Academician N. F. Miasoedov**, and K. S. Rayevsky* Received June 11, 2003 Short-term effects of the synthetic nootropic peptide in rats and simultaneously raises the intracellular level Semax on the content and metabolism of monoamines of dopamine in the striatum [6]. in the brain of C57/Bl6 mice and Sprague–Dawley rats The goal of this study was to examine the effects of were studied. Intraperitoneal injection of Semax at a Semax on the neurochemical parameters of the dopam- dose of 0.15 mg/kg caused an increase in the tissue con- inergic and serotoninergic systems of the animal brain. centrations of 5-hydroxyindoleacetic acid (5-HIAA) in Semax was administered at a dose of 0.15 mg per kilo- the hypothalamus and striatum of mice 0.5 and 2 h after gram body weight to ë57/Bl6 mice, and their hypothal- the injection. Using brain microdialysis, we detected amus and striatum were analyzed for tissue levels of increased levels of extracellular 5-HIAA in the striatum dopamine (DA) and its metabolites 3,4-dihydroxyphe- of freely moving rats 1 h after administration of 0.15 or nylacetic acid (DOPAC) and homovanillic acid (HVA), 0.6 mg/kg Semax. The effect lasted for an additional as well as serotonin (or 5-hydroxytriptamine, 5-HT) 3 h.
    [Show full text]
  • Screening of 109 Neuropeptides on Asics Reveals No Direct Agonists
    www.nature.com/scientificreports OPEN Screening of 109 neuropeptides on ASICs reveals no direct agonists and dynorphin A, YFMRFamide and Received: 7 August 2018 Accepted: 14 November 2018 endomorphin-1 as modulators Published: xx xx xxxx Anna Vyvers, Axel Schmidt, Dominik Wiemuth & Stefan Gründer Acid-sensing ion channels (ASICs) belong to the DEG/ENaC gene family. While ASIC1a, ASIC1b and ASIC3 are activated by extracellular protons, ASIC4 and the closely related bile acid-sensitive ion channel (BASIC or ASIC5) are orphan receptors. Neuropeptides are important modulators of ASICs. Moreover, related DEG/ENaCs are directly activated by neuropeptides, rendering neuropeptides interesting ligands of ASICs. Here, we performed an unbiased screen of 109 short neuropeptides (<20 amino acids) on fve homomeric ASICs: ASIC1a, ASIC1b, ASIC3, ASIC4 and BASIC. This screen revealed no direct agonist of any ASIC but three modulators. First, dynorphin A as a modulator of ASIC1a, which increased currents of partially desensitized channels; second, YFMRFamide as a modulator of ASIC1b and ASIC3, which decreased currents of ASIC1b and slowed desensitization of ASIC1b and ASIC3; and, third, endomorphin-1 as a modulator of ASIC3, which also slowed desensitization. With the exception of YFMRFamide, which, however, is not a mammalian neuropeptide, we identifed no new modulator of ASICs. In summary, our screen confrmed some known peptide modulators of ASICs but identifed no new peptide ligands of ASICs, suggesting that most short peptides acting as ligands of ASICs are already known. Acid-sensing ion channels form a small family of proton-gated ion channels that belongs to the degenerin/epi- thelial Na+ channel (DEG/ENaC) gene family1.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,345,661 B2 Adler Et Al
    USOO9345661 B2 (12) United States Patent (10) Patent No.: US 9,345,661 B2 Adler et al. (45) Date of Patent: May 24, 2016 (54) SUBCUTANEOUSANTI-HER2 ANTIBODY FOREIGN PATENT DOCUMENTS FORMULATIONS AND USES THEREOF CL 2756-2005 10/2005 CL 561-2011 3, 2011 (75) Inventors: Michael Adler, Riehen (CH); Ulla CL 269-2012 1, 2012 Grauschopf, Riehen (CH): CN 101163717 4/2008 Hanns-Christian Mahler, Basel (CH): CN 101370525 2, 2009 Oliver Boris Stauch, Freiburg (DE) EP O590058 B1 11, 2003 EP 1516628 B1 3, 2005 (73) Assignee: Genentech, Inc., South San Francisco, EP 1603541 11, 2009 JP 2007-533631 11, 2007 CA (US) JP 2008-5075.20 3, 2008 JP 2008-528638 T 2008 (*) Notice: Subject to any disclaimer, the term of this JP 2009-504142 2, 2009 patent is extended or adjusted under 35 JP 2009/055343 4/2009 U.S.C. 154(b) by 0 days. KR 2007-0068385 6, 2007 WO 93.21319 A1 10, 1993 WO 94/OO136 A1 1, 1994 (21) Appl. No.: 12/804,703 WO 97.048O1 2, 1997 WO 98.22136 5, 1998 (22) Filed: Jul. 27, 2010 WO 99.57134 11, 1999 WO 01.00245 A2 1, 2001 (65) Prior Publication Data WO 2004/078140 9, 2004 WO 2005/023328 3, 2005 US 2011 FOO44977 A1 Feb. 24, 2011 WO 2005/037992 A2 4/2005 WO 2005,117986 12/2005 (30) Foreign Application Priority Data WO WO 2005,117986 A2 * 12/2005 WO 2006/044908 A2 4/2006 Jul. 31, 2009 (EP) ..................................... 0.9167025 WO 2006/09 1871 8, 2006 WO 2007 O24715 3, 2007 (51) Int.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0337042 A1 Reilly Et Al
    US 2015 0337042A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0337042 A1 Reilly et al. (43) Pub. Date: Nov. 26, 2015 (54) ANTI-EGFRANTIBODIES AND ANTIBODY (22) Filed: Mar. 20, 2015 DRUG CONUGATES Related U.S. Application Data (71) Applicant: ABBVIE INC., North Chicago, IL (US) (60) Provisional application No. 61/968,819, filed on Mar. 21, 2014. (72) Inventors: Edward B. Reilly, Libertyville, IL (US); Publication Classification Andrew C. Phillips, Libertyville, IL (US); Lorenzo Benatuil, Northborough, (51) Int. Cl. MA (US); Fritz G. Buchanan, Antioch, C07K 6/28 (2006.01) IL (US); Jonathan A. Meulbroek, Lake A647/48 (2006.01) Bluff, IL (US); Chung-Ming Hsieh, (52) U.S. Cl. Newton, MA (US); Jennifer Perez, CPC ....... C07K 16/2863 (2013.01); A61K 47/48561 (2013.01); C07K 2317/21 (2013.01); C07K Granville, NY (US) 231 7/565 (2013.01) (57) ABSTRACT (73) Assignee: ABBVIE INC., North Chicago, IL (US) The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and (21) Appl. No.: 14/664,453 ADCs. Patent Application Publication Nov. 26, 2015 Sheet 1 of 24 US 2015/0337042 A1 8HODZHOD|HCJD |?un6|+ Patent Application Publication Nov. 26, 2015 Sheet 4 of 24 US 2015/0337042 A1 FACS Binding to Tumor Cells 1 OOOO 7500 5OOO 25OO O.O1 1 100 1 OOOO Patent Application Publication Nov. 26, 2015 Sheet 5 of 24 US 2015/0337042 A1 009/ ueeu Oed Patent Application Publication Nov. 26, 2015 Sheet 6 of 24 US 2015/0337042 A1 EGFR (1-525) Binding kinetics (closed circles) = Ab1 and Ab2 106 (open circles) = variants Figure 6 Patent Application Publication Nov.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats
    G C A T T A C G G C A T genes Article Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats Ivan B. Filippenkov 1,* , Vasily V. Stavchansky 1, Alina E. Denisova 2, Vadim V. Yuzhakov 3, Larisa E. Sevan’kaeva 3, Olga Y. Sudarkina 1 , Veronika G. Dmitrieva 1, Leonid V. Gubsky 2, Nikolai F. Myasoedov 1, Svetlana A. Limborska 1 and Lyudmila V. Dergunova 1 1 Institute of Molecular Genetics, Russian Academy of Sciences, 123182 Moscow, Russia; [email protected] (V.V.S.); [email protected] (O.Y.S.); [email protected] (V.G.D.); [email protected] (N.F.M.); [email protected] (S.A.L.); [email protected] (L.V.D.) 2 Pirogov Russian National Research Medical University, Federal Center of Cerebrovascular Pathology and Stroke, Ministry of Health Care of Russian Federation, 117342 Moscow, Russia; [email protected] (A.E.D.); [email protected] (L.V.G.) 3 A. Tsyb Medical Radiological Research Center–Branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, 249031 Obninsk, Russia; [email protected] (V.V.Y.); [email protected] (L.E.S.) * Correspondence: fi[email protected]; Tel.: +7-499-196-1858 Received: 16 May 2020; Accepted: 18 June 2020; Published: 22 June 2020 Abstract: Cerebral ischaemia is the most common cause of impaired brain function. Biologically active peptides represent potential drugs for reducing the damage that occurs after ischaemia. The synthetic melanocortin derivative, ACTH(4-7)PGP (Semax), has been used successfully in the treatment of patients with severe impairment of cerebral blood circulation.
    [Show full text]
  • Wells Pharmacy Network Master Formulary 7-27-2020 Without Pricing
    BHRT Pellets & Numbing Cream Medication Form Strength Pellet Size (mm) 6 mg (3 mm) 10 mg (3 mm) 12.5 mg (3 mm) Estradiol Pellet 15 mg (3 mm) 18 mg (3 mm) 20 mg (3 mm) 25 mg (3 mm) 50 mg (3 mm) Progesterone Pellet 100 mg (3 mm) 12.5 mg (3 mm) 25 mg (3 mm) 37.5 mg (3 mm) 50 mg (3 mm) Testosterone Pellet 62.5 mg (3 mm) 87.5 mg (3 mm) 100 mg (3 mm) 200 mg (4.5 mm) 100 mg / 4 mg (3 mm) Testosterone / Anastrozole Pellet 200 mg / 8 mg (4.5 mm) 200 mg / 20 mg (4.5 mm) Disposable - Each Plastic Tip (3.2 mm) Disposable - Stainless Steel Tip Each Trocar Kit for Pellet Insertion Trocar (3.2 mm & 4.5 mm) Reusable - Titanium Or Each Stainless Steel (3.2 mm & 4.5 mm) 3.2 mm Trocars are meant to be used with 3 mm Pellets & 4.5 mm Trocars are meant to be used with 4.5 mm Pellets Medication Form Strength Package Size Cream Benzocaine / Lidocaine/ Tetracaine 20% / 6% / 4% 120 gm Topi-Pump® Items marked in Yellow: (new items added with-in 90 days) Price effective July 27th, 2020 | Pricing Subject to Change | Products may be subject to additional fees based on availability 503B IV Therapy Medication Form Strength Package Size Arginine IV 100 mg / ml 30 mL Glutathione IV 200 mg / ml 30 mL Lipoic Acid (DL-Thioctic Acid) IV 2.5% (25 mg / ml) 30 mL Methylcobalamin IV 1000 mcg / ml 10 mL Pyridoxine HCL IV 100 mg / ml 30 mL Taurine IV 50 mg/ ml 30 mL Items marked in Yellow: (new items added with-in 90 days) Price effective July 27th, 2020 | Pricing Subject to Change | Products may be subject to additional fees based on availability Peptides Package Medication Form
    [Show full text]
  • Efficacy of Peptide Anxiolytic Selank During Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation
    52 Bulletin of Experimental Biology and Medicine, Vol. 157, No. 1, May, 2014 PHARMACOLOGY AND TOXICOLOGY Effi cacy of Peptide Anxiolytic Selank during Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation L. G. Kolik, A. V. Nadorova, and M. M. Kozlovskaya Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 1567, No. 1, pp. 61-65, January, 2014 Original article submitted January 31, 2013 We studied the effects of selank on the development of symptoms of acute 48-h alcohol withdrawal in outbred rats drinking 10% ethanol as the only source of fl uid for 24 weeks. In alcohol-preferring animals (mean daily ethanol intake >5.0 g/kg) allowed free choice between 10% ethanol and water, single intraperitoneal injection of selank in a dose of 0.3 mg/kg eliminated anxiety induced by ethanol withdrawal in tests elevated plus maze and so- cial interaction tests and prevented the formation of mechanical allodynia without affecting ethanol consumption. The fi ndings suggest that selank is effective in eliminating of alcohol withdrawal symptoms in rats. Key Words: selank; alcohol withdrawal; anxiety; allodynia; rats Benzodiazepine anxiolytics temporary relieving man- by rapid onset of therapeutic effect and the absence of ifestation of psychopathological symptoms associ- undesirable side effects [4]. Experimental studies have ated with withdrawal syndrome play an important shown that it had a broad spectrum of psychotropic role in the complex medical therapy for alcoholism. activity and restored integrative activity of the CNS However, numerous side effects, such as respiratory impaired by neurotoxic factors of different genesis depression, excitement, potentiation of the narcogene [5].
    [Show full text]